The short answer
Guarana contains caffeine, which can aggravate restless legs symptoms. If you take ropinirole for restless legs syndrome, review guarana and your other caffeine sources with your clinician. Increased ropinirole levels or toxicity from this pair have not been established.
What this answer covers
Paullinia cupana seed preparations containing caffeine; the actual amount depends on the product.
- Supplement or preparation
- Paullinia cupana
- Medication ingredient
- ropinirole
Guarana contributes to total caffeine
Guarana seed contains caffeine. Check the amount in your actual serving and any added caffeine in a mixed product. A raw-seed specification does not tell you the amount in every supplement.
Why this matters for restless legs syndrome
The American Academy of Sleep Medicine recommends addressing caffeine as a factor that can worsen restless legs symptoms. This advice applies when ropinirole is being used for that condition; it is not evidence that guarana raises ropinirole levels.
What the safety review does and does not show
The European review noted reports of palpitations plausibly related to caffeine. These reports cannot measure the risk with ropinirole. Animal findings involving a different medicine do not establish this interaction or a useful spacing interval.
Do not use a stimulant to manage a sleep episode
If you become markedly sleepy or fall asleep during ordinary activities, do not drive. Contact your prescriber promptly to review ropinirole and the treatment plan; relying on a caffeine product is not an established way to manage this warning.
Evidence and practical considerations
Side effects & toxicity
Caffeine-related restless legs symptom management is relevant; a direct ropinirole pharmacokinetic interaction is unproven.
- Exact scope
- Paullinia cupana seed preparations containing caffeine; the actual amount depends on the product. with Oral immediate-release ropinirole, with hydrochloride salt expressed as equivalent free base in label section 11.
- Medication form and route
- oral
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- Guideline advice addresses the disease, not drug concentrations. No human exact-pair trial identified.
Factors that may matter: baseline alertness; exact preparation; other medicines; treatment indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
No direct study of these six supplement combinations. Immediate-release tablet context does not establish release-form or dose interchangeability.
Source 2: official guidance
ema.europa.eu · Source check Sep 10, 2026
Population: People considering the specified supplement.
Identifies caffeine in guarana seed; a pharmacopoeial seed specification requires at least 3.5% caffeine.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
A raw-material specification is not the caffeine amount in every commercial serving. No ropinirole study.
Source 3: official guidance
ema.europa.eu · Source check Sep 10, 2026
Population: People considering the specified supplement.
Review noted palpitations reports plausibly related to caffeine and no new safety concern requiring monograph revision. Rat amiodarone results were not adopted as clinical interaction guidance.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Spontaneous reports cannot quantify risk; rat amiodarone findings do not establish a human ropinirole interaction.
Source 4: American Academy of Sleep Medicine clinical practice guideline
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults and children with restless legs syndrome or periodic limb movement disorder.
Good practice statement recommends addressing exacerbating factors including caffeine. Standard ropinirole use in adult RLS receives a conditional recommendation against because of longer-term concerns, particularly augmentation.
How this applies: Relevant only when ropinirole is being used for RLS; not a Parkinson disease caffeine prohibition.
Disease-management guidance, not evidence that caffeine increases ropinirole concentrations or toxicity. The caffeine statement is expert consensus.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Targeted sources inspected and all current available claims adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: 4a9e66f372fb00e5
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.